Compare · BNTX vs TECX
BNTX vs TECX
Side-by-side comparison of BioNTech SE (BNTX) and Tectonic Therapeutic Inc. (TECX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and TECX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $22.66B, about 54.4x TECX ($416.4M).
- Over the past year, BNTX is down 16.6% and TECX is up 19.9% - TECX leads by 36.5 points.
- BNTX has been more active in the news (11 items in the past 4 weeks vs 8 for TECX).
- BNTX has more recent analyst coverage (25 ratings vs 12 for TECX).
- Company
- BioNTech SE
- Tectonic Therapeutic Inc.
- Price
- $87.69-2.80%
- $20.67-2.82%
- Market cap
- $22.66B
- $416.4M
- 1M return
- -11.18%
- -24.09%
- 1Y return
- -16.64%
- +19.86%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2018
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 12
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
- SEC Form 4 filed by BioNTech SE
- Argus initiated coverage on BioNTech
- SEC Form 4 filed by BioNTech SE
- SEC Form 4 filed by BioNTech SE
- Chief Executive Officer Sahin Ugur sold $3,301,068 worth of Ordinary Shares (34,000 units at $97.09) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 180,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,480,659 worth of Ordinary Shares (66,000 units at $98.19) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 214,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,012,500 worth of Ordinary Shares (61,000 units at $98.57) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 280,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,842,742 worth of Ordinary Shares (69,000 units at $99.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 341,209 units (SEC Form 4)
Latest TECX
- UBS initiated coverage on Tectonic Therapeutic with a new price target
- Chief Financial Officer Lochner Daniel covered exercise/tax liability with 520 shares, decreasing direct ownership by 0.89% to 58,024 units (SEC Form 4) to cover taxes
- Chief Scientific Officer Mcnamara Peter covered exercise/tax liability with 444 shares and sold $12,349 worth of shares (536 units at $23.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 54,305 units (SEC Form 4) to cover withholding tax
- Chief Medical Officer Ruddy Marcella K. covered exercise/tax liability with 525 shares, decreasing direct ownership by 0.78% to 67,157 units (SEC Form 4) to satisfy withholding tax
- Chief Executive Officer Reicin Alise covered exercise/tax liability with 1,545 shares, decreasing direct ownership by 0.50% to 309,078 units (SEC Form 4) (for withholding tax)
- Chief Business Officer Schwabish Marc covered exercise/tax liability with 411 shares, decreasing direct ownership by 0.91% to 44,903 units (SEC Form 4) (withholding obligation)
- SEC Form 8-K filed by Tectonic Therapeutic Inc.
- Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
- SEC Form 4 filed by Chief Executive Officer Reicin Alise
- SEC Form 4 filed by Chief Medical Officer Ruddy Marcella K.